Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting

Sana Biotechnology, Inc. (NASDAQ:SANA) ranks among the best CRISPR stocks to buy. On June 24, Citizens JMP reaffirmed its $5 price target and Market Outperform rating for Sana Biotechnology, Inc. (NASDAQ:SANA) in light of new clinical data from its diabetes therapy program.

The biotechnology company attended the American Diabetes Association meeting and presented new results from its UP421 cadaveric pancreatic islet cell program. The findings showed that people with Type 1 diabetes can still safely and well tolerate islet cells.

At the 24-week milestone, the findings indicated that the transplanted cells were still alive and generating insulin without the need for immunosuppression, according to Citizens JMP. This was verified by MRI imaging, mixed-meal tolerance testing, and baseline C-peptide levels.

Sana Biotechnology, Inc. (NASDAQ:SANA) is a Seattle, Washington-based company that specializes in developing treatments for complex diseases like diabetes, cancer, and nervous system disorders. The company’s potential for success is largely influenced by its R&D pipeline. Back in 2021, the company inked a deal with Beam Therapeutics for the non-exclusive commercial rights to the biotech’s CRISPR-Cas12b gene editing system.

While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.